14-15 November 2018
|European Case Law Identifier:||ECLI:EP:BA:2008:T160207.20080117|
|Date of decision:||17 January 2008|
|Case number:||T 1602/07|
|IPC class:||C07D 417/12|
|Language of proceedings:||EN|
|Download and more information:||
|Title of application:||Novel crystalline form of 5-(4-((3-methyl-4-oxo-3,4-dihydroquinazolin-2- yl)methoxy)benzyl)thiazolidine-2,4-dione potassium salt|
|Applicant name:||Dr. Reddy's Laboratories Ltd.|
|Relevant legal provisions:||
|Keywords:||Missing statement of grounds|
Summary of Facts and Submissions
I. The appeal contests the decision of the Examining Division of the European Patent Office dispatched by registered letter with advice of delivery to the Applicant on 27 March 2007, refusing the European Patent Application No. 03744465.0.
The Appellant filed a Notice of Appeal by a letter received on 21 May 2007 and paid the fee for appeal on the same day. No Statement of Grounds was filed. The Notice of Appeal contains nothing that could be regarded as a Statement of Grounds pursuant to Article 108 EPC.
II. By a communication dated 28 September 2007, sent by registered post, the Registrar of the Board informed the Appellant that no Statement of Grounds has been filed and that the appeal could be expected to be rejected as inadmissible. The Appellant was informed about the possibility of filing a request for re-establishment of rights under Article 122 EPC 1973 and was invited to file observations within two months.
III. No answer has been given within the given time limit to the Registry's communication.
Reasons for the Decision
As no written statement setting out the grounds of appeal has been filed, the appeal has to be rejected as inadmissible (Article 108 EPC in conjunction with Rule 101(1) EPC (formerly Rule 65(1) EPC 1973)).
For these reasons it is decided that:
The appeal is rejected as inadmissible.